Positive lung drug trial opens path to U.S. market for Circassia
September 07, 2017 at 02:48 AM EDT
LONDON, Sept 7 (Reuters) - AstraZeneca said its drug Duaklir improved lung function in chronic obstructive pulmonary disease (COPD) patients in a new study, paving the way for a submission in the United States where the rights are held by Britain's Circassia.
